Cryptococcosis diagnosis and treatment: What do we know now

被引:145
|
作者
Perfect, John R. [1 ]
Bicanic, Tihana [2 ]
机构
[1] Duke Univ, Med Ctr, Dept Med, Div Infect Dis, Durham, NC 27710 USA
[2] Univ London, Inst Infect & Immun, London, England
关键词
Medical mycology; Management; Meningitis; Pathophysiology; HIGH-DOSE FLUCONAZOLE; COURSE AMPHOTERICIN-B; HIV-INFECTED PATIENTS; INTRACRANIAL-PRESSURE; ANTIFUNGAL THERAPIES; FUNGAL BURDEN; LATERAL FLOW; MENINGITIS; NEOFORMANS; AIDS;
D O I
10.1016/j.fgb.2014.10.003
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Cryptococcosis has evolved into a major invasive fungal disease over the last century. Its primary epidemiology has been focused on three major outbreaks of disease that reflects both changing environmental exposures and growth of host risk factors. The molecular understandings of yeast pathobiology have been bolstered by identification of the yeast's dynamic genomic structures and functions. It is during these new insights into epidemiology and pathobiology that we have also improved our diagnosis of this infection with a new point-of-care, simple, cheap test which utilizes a lateral flow assay for antigen detection. With methods for effective identification of Cryptococcus in the host, the principles for management of this deadly infection include both use of old drugs and new insights into treatment strategies to improve outcome. In this review there are a series of recent insights, opinions, and facts which attempt to summarize our present knowledge base for this deadly fungal central nervous system infection with a particular emphasis on its diagnosis and management. (C) 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
引用
收藏
页码:49 / 54
页数:6
相关论文
共 50 条
  • [31] What do we know? What do we need to know?
    Henzlova, Milena J.
    Duvall, W. Lane
    JOURNAL OF NUCLEAR CARDIOLOGY, 2017, 24 (01) : 252 - 254
  • [32] Healthy sexual life after a cardiac event: What do we know and what do we do now?
    Fridlund, Bengt
    EUROPEAN JOURNAL OF CARDIOVASCULAR NURSING, 2009, 8 (03) : 159 - 160
  • [33] NOW THAT WE KNOW HOW LOW THE RELIABILITY IS, WHAT SHALL WE DO
    SALZINGER, K
    BEHAVIORAL AND BRAIN SCIENCES, 1991, 14 (01) : 162 - 162
  • [34] Long COVID: what do we know now and what are the challenges ahead?
    Pereira, Snehal M. Pinto
    Newlands, Fiona
    Anders, Jake
    Banerjee, Amitava
    Blandford, Ann
    Brown, Kate
    Beale, Sarah
    Bu, Feifei
    Fong, Wing Lam Erica
    Gilpin, Gina
    Hardelid, Pia
    Kovar, Jana
    Lim, Jason
    Park, Chloe
    Raveendran, Vishnuga
    Shah, Anoop D.
    Shao, Xin
    Wong, Andrew
    Stephenson, Terence
    Shafran, Roz
    JOURNAL OF THE ROYAL SOCIETY OF MEDICINE, 2024, 117 (07) : 224 - 228
  • [35] Genetic platforms: Do we do what we know? or do we know what we do?
    Bernet, Laia
    Pla, Maria Jesus
    Janez, Noelia Martinez
    REVISTA DE SENOLOGIA Y PATOLOGIA MAMARIA, 2021, 34 (02): : 100 - 110
  • [36] Treatment selection: What do we know?
    Vervaeke, GAC
    Emmelkamp, PMG
    EUROPEAN JOURNAL OF PSYCHOLOGICAL ASSESSMENT, 1998, 14 (01) : 50 - 59
  • [37] COVID-19 and Dialysis Units: What Do We Know Now and What Should We Do?
    Ikizler, T. Alp
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2020, 76 (01) : 1 - 3
  • [38] Quasicrystals: What do we know? What do we want to know? What can we know?
    Steurer, Walter
    ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES, 2018, 74 : 1 - 11
  • [39] Diagnosis and treatment of thyroid disorders in obese patients - what do we know?
    Gajda, Sylwia N.
    Kurylowicz, Alina
    Zach, Marcin
    Bednarczuk, Tomasz
    Wylezol, Mariusz
    ENDOKRYNOLOGIA POLSKA, 2019, 70 (03) : 270 - 276
  • [40] WHAT DO WE KNOW ABOUT DEPRESSION .2. DIAGNOSIS AND TREATMENT
    GARFIELD, E
    CURRENT CONTENTS, 1981, (20): : 5 - 12